Skip to main content
Top
Published in: BMC Nephrology 1/2014

Open Access 01-12-2014 | Research article

Guideline adherence for identification and hydration of high-risk hospital patients for contrast-induced nephropathy

Authors: Janneke Schilp, Carolien de Blok, Maaike Langelaan, Peter Spreeuwenberg, Cordula Wagner

Published in: BMC Nephrology | Issue 1/2014

Login to get access

Abstract

Background

Contrast-induced nephropathy (CIN) is a common cause of acute renal failure in hospital patients. To prevent CIN, identification and hydration of high-risk patients is important. Prevention of CIN by hydration of high-risk patients was one of the themes to be implemented in the Dutch Hospital Patient Safety Program. This study investigates to what extent high-risk patients are identified and hydrated before contrast administration. Hospital-related and admission-related factors associated with the hydration of high-risk patients are identified.

Methods

The adherence to the guideline concerning identification and hydration of high-risk patients for CIN was evaluated retrospectively in 4297 patient records between November 2011 and December 2012. A multilevel logistic regression analysis was used to investigate the association between hospital-related and patient-related factors and hydration.

Results

The mean percentage patients with a known estimated Glomerular Filtration Rate before contrast administration was 96.4%. The mean percentage high-risk patients for CIN was 14.6%. The mean percentage high-risk patients hydrated before contrast administration was 68.5% and was constant over time. Differences between individual hospitals explained 19% of the variation in hydration. The estimated Glomerular Filtration Rate value and admission department were statistically significantly associated with the execution of hydration.

Conclusion

The identification of high-risk patients was almost 100%, but the subsequent step in the prevention of CIN is less performed, as only two third of the high-risk patients were hydrated before contrast administration. Large variation between individual hospitals confirmed the difference in hospitals in correctly applying the guideline for preventing CIN.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G: A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004, 44: 1393-1399.PubMed Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G: A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004, 44: 1393-1399.PubMed
2.
go back to reference Lasser EC, Lyon SG, Berry CC: Reports on contrast media reactions: analysis of data from reports to the U.S. Food and drug administration. Radiology. 1997, 203: 605-610.CrossRefPubMed Lasser EC, Lyon SG, Berry CC: Reports on contrast media reactions: analysis of data from reports to the U.S. Food and drug administration. Radiology. 1997, 203: 605-610.CrossRefPubMed
3.
go back to reference Chong E, Shen L, Poh KK, Tan HC: Risk scoring system for prediction of contrast-induced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention. Singapore Med J. 2012, 53: 164-169.PubMed Chong E, Shen L, Poh KK, Tan HC: Risk scoring system for prediction of contrast-induced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention. Singapore Med J. 2012, 53: 164-169.PubMed
4.
go back to reference Mehran R, Nikolsky E: Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006, S11-S15. 100 Mehran R, Nikolsky E: Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006, S11-S15. 100
5.
go back to reference McCullough PA: Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008, 51: 1419-1428. 10.1016/j.jacc.2007.12.035.CrossRefPubMed McCullough PA: Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008, 51: 1419-1428. 10.1016/j.jacc.2007.12.035.CrossRefPubMed
6.
go back to reference Bagshaw SM, Culleton BF: Contrast-induced nephropathy: epidemiology and prevention. Minerva Cardioangiol. 2006, 54: 109-129.PubMed Bagshaw SM, Culleton BF: Contrast-induced nephropathy: epidemiology and prevention. Minerva Cardioangiol. 2006, 54: 109-129.PubMed
7.
go back to reference Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, Lansky AJ, Moussa I, Stone GW, Moses JW, Leon MB, Mehran R: Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005, 95: 13-19. 10.1016/j.amjcard.2004.08.056.CrossRefPubMed Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, Lansky AJ, Moussa I, Stone GW, Moses JW, Leon MB, Mehran R: Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005, 95: 13-19. 10.1016/j.amjcard.2004.08.056.CrossRefPubMed
8.
go back to reference Li JH, He NS: Prevention of iodinated contrast-induced nephropathy. Chin Med J (Engl). 2011, 124: 4079-4082. Li JH, He NS: Prevention of iodinated contrast-induced nephropathy. Chin Med J (Engl). 2011, 124: 4079-4082.
9.
go back to reference Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR: Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2009, 53: 617-627. 10.1053/j.ajkd.2008.08.033.CrossRefPubMed Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR: Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2009, 53: 617-627. 10.1053/j.ajkd.2008.08.033.CrossRefPubMed
10.
go back to reference Bader BD, Berger ED, Heede MB, Silberbaur I, Duda S, Risler T, Erley CM: What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?. Clin Nephrol. 2004, 62: 1-7. 10.5414/CNP62001.CrossRefPubMed Bader BD, Berger ED, Heede MB, Silberbaur I, Duda S, Risler T, Erley CM: What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?. Clin Nephrol. 2004, 62: 1-7. 10.5414/CNP62001.CrossRefPubMed
11.
go back to reference Chen SL, Zhang J, Yei F, Zhu Z, Liu Z, Lin S, Chu J, Yan J, Zhang R, Kwan TW: Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine. Int J Cardiol. 2008, 126: 407-413. 10.1016/j.ijcard.2007.05.004.CrossRefPubMed Chen SL, Zhang J, Yei F, Zhu Z, Liu Z, Lin S, Chu J, Yan J, Zhang R, Kwan TW: Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine. Int J Cardiol. 2008, 126: 407-413. 10.1016/j.ijcard.2007.05.004.CrossRefPubMed
12.
go back to reference Krasuski RA, Beard BM, Geoghagan JD, Thompson CM, Guidera SA: Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J Invasive Cardiol. 2003, 15: 699-702.PubMed Krasuski RA, Beard BM, Geoghagan JD, Thompson CM, Guidera SA: Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J Invasive Cardiol. 2003, 15: 699-702.PubMed
13.
go back to reference Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, Marsch S, Roskamm H: Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002, 162: 329-336. 10.1001/archinte.162.3.329.CrossRefPubMed Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, Marsch S, Roskamm H: Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002, 162: 329-336. 10.1001/archinte.162.3.329.CrossRefPubMed
14.
go back to reference Taylor AJ, Hotchkiss D, Morse RW, McCabe J: PREPARED: preparation for angiography in renal dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest. 1998, 114: 1570-1574. 10.1378/chest.114.6.1570.CrossRefPubMed Taylor AJ, Hotchkiss D, Morse RW, McCabe J: PREPARED: preparation for angiography in renal dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest. 1998, 114: 1570-1574. 10.1378/chest.114.6.1570.CrossRefPubMed
15.
go back to reference Trivedi HS, Moore H, Nasr S, Aggarwal K, Agrawal A, Goel P, Hewett J: A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract. 2003, 93: C29-C34. 10.1159/000066641.CrossRefPubMed Trivedi HS, Moore H, Nasr S, Aggarwal K, Agrawal A, Goel P, Hewett J: A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract. 2003, 93: C29-C34. 10.1159/000066641.CrossRefPubMed
17.
go back to reference Dutch Institute for Healthcare Improvement CBO: Richtlijn Voorzorgsmaatregelen bij jodiumhoudende contrastmiddelen (in English: Guideline preventing methods with contrast medium administration). 2007, Utrecht, The Netherlands Dutch Institute for Healthcare Improvement CBO: Richtlijn Voorzorgsmaatregelen bij jodiumhoudende contrastmiddelen (in English: Guideline preventing methods with contrast medium administration). 2007, Utrecht, The Netherlands
18.
go back to reference VMS: Prevention of contrast-induced renal failure. 2009, Utrecht, The Netherlands: VMS Zorg VMS: Prevention of contrast-induced renal failure. 2009, Utrecht, The Netherlands: VMS Zorg
19.
20.
go back to reference Grimshaw JM, Russell IT: Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet. 1993, 342: 1317-1322. 10.1016/0140-6736(93)92244-N.CrossRefPubMed Grimshaw JM, Russell IT: Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet. 1993, 342: 1317-1322. 10.1016/0140-6736(93)92244-N.CrossRefPubMed
21.
go back to reference McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, Tumlin J: Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006, 98: 27K-36K.CrossRefPubMed McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, Tumlin J: Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006, 98: 27K-36K.CrossRefPubMed
22.
go back to reference Toprak O: Conflicting and new risk factors for contrast induced nephropathy. J Urol. 2007, 178: 2277-2283. 10.1016/j.juro.2007.08.054.CrossRefPubMed Toprak O: Conflicting and new risk factors for contrast induced nephropathy. J Urol. 2007, 178: 2277-2283. 10.1016/j.juro.2007.08.054.CrossRefPubMed
23.
go back to reference De Blok C, Koster E, Schilp J, Wagner C: Implementation VMS safety program, evaluation study in dutch hospitals (in dutch: implementatie VMS veiligheidsprogramma, evaluatieonderzoek in nederlandse ziekenhuizen). 2013, Utrecht/Amsterdam, The Netherlands: NIVEL/EMGO+, English summary on http://www.nivel.nl De Blok C, Koster E, Schilp J, Wagner C: Implementation VMS safety program, evaluation study in dutch hospitals (in dutch: implementatie VMS veiligheidsprogramma, evaluatieonderzoek in nederlandse ziekenhuizen). 2013, Utrecht/Amsterdam, The Netherlands: NIVEL/EMGO+, English summary on http://​www.​nivel.​nl
24.
go back to reference Twisk JW: Applied multilevel analysis: a practical guide. 2006, Cambridge: Cambridge University PressCrossRef Twisk JW: Applied multilevel analysis: a practical guide. 2006, Cambridge: Cambridge University PressCrossRef
25.
go back to reference Calabro P, Bianchi R, Crisci M, Caprile M, Bigazzi MC, Palmieri R, Golia E, De VA, Romano IJ, Limongelli G, Russo MG, Calabro R: Use and efficacy of saline hydration and N-acetyl cysteine to prevent contrast-induced nephropathy in low-risk populations undergoing coronary artery angiography. Intern Emerg Med. 2011, 6: 503-507. 10.1007/s11739-011-0513-y.CrossRefPubMed Calabro P, Bianchi R, Crisci M, Caprile M, Bigazzi MC, Palmieri R, Golia E, De VA, Romano IJ, Limongelli G, Russo MG, Calabro R: Use and efficacy of saline hydration and N-acetyl cysteine to prevent contrast-induced nephropathy in low-risk populations undergoing coronary artery angiography. Intern Emerg Med. 2011, 6: 503-507. 10.1007/s11739-011-0513-y.CrossRefPubMed
26.
go back to reference Kooiman J, Van der Molen AJ, Cannegieter SZ, Rabelink TJ: Prevention of contrast-induced nephropathy, time for nuance and a new guideline (in Dutch: Preventie van contrastnefropathie, tijd voor nuance en een nieuwe richtlijn). Ned Tijdschr Geneesk. 2013, 157 (12): A5475- Kooiman J, Van der Molen AJ, Cannegieter SZ, Rabelink TJ: Prevention of contrast-induced nephropathy, time for nuance and a new guideline (in Dutch: Preventie van contrastnefropathie, tijd voor nuance en een nieuwe richtlijn). Ned Tijdschr Geneesk. 2013, 157 (12): A5475-
Metadata
Title
Guideline adherence for identification and hydration of high-risk hospital patients for contrast-induced nephropathy
Authors
Janneke Schilp
Carolien de Blok
Maaike Langelaan
Peter Spreeuwenberg
Cordula Wagner
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2014
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-15-2

Other articles of this Issue 1/2014

BMC Nephrology 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.